Quarterly ResultMay 14, 2026, 04:47 PM
NuCana Q1 Net Loss £3.9M; Cash Runway into 2029; NUC-7738 FDA IND Clear
AI Summary
NuCana plc reported a net loss of £3.9 million for the first quarter of 2026, an increase from £2.5 million in the prior year period, driven by higher research and development and administrative expenses. Despite the increased loss and a decrease in cash and cash equivalents to £21.5 million, the company announced its cash runway is expected to extend into 2029. Key business updates include the FDA clearance of its Investigational New Drug application for NUC-7738 in April 2026, with final data from the Phase 2 expansion study in melanoma anticipated later in 2026.
Key Highlights
- Net loss for Q1 2026 was £3.9 million, compared to £2.5 million for Q1 2025.
- Cash and cash equivalents totaled £21.5 million as of March 31, 2026, down from £24.3 million at December 31, 2025.
- Cash resources are expected to fund planned operations into 2029.
- FDA IND application for NUC-7738 was cleared in April 2026, enabling US clinical investigation.
- Final data from the Phase 2 expansion study of NUC-7738 in melanoma is expected later in 2026.
- Research and development expenses increased to £3.213 million in Q1 2026 from £1.725 million in Q1 2025.
- Administrative expenses rose to £1.568 million in Q1 2026 from £1.067 million in Q1 2025.
- Share-based payment expenses were £1.9 million in Q1 2026, up from £0.3 million in Q1 2025.